Abeona Therapeutics (NASDAQ:ABEO) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Thursday.
A number of other equities research analysts have also recently issued reports on ABEO. Maxim Group set a $35.00 price objective on Abeona Therapeutics and gave the stock a “buy” rating in a report on Monday, March 19th. Cantor Fitzgerald set a $36.00 price target on Abeona Therapeutics and gave the company a “buy” rating in a research note on Tuesday, March 20th. Zacks Investment Research cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 21st. HC Wainwright set a $30.00 price target on Abeona Therapeutics and gave the company a “buy” rating in a research note on Monday, April 2nd. Finally, ValuEngine upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $28.30.
Shares of NASDAQ:ABEO opened at $16.00 on Thursday. Abeona Therapeutics has a 12-month low of $6.12 and a 12-month high of $22.75. The company has a market cap of $745.06 million, a PE ratio of -24.24 and a beta of 1.27.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Abeona Therapeutics had a negative return on equity of 23.57% and a negative net margin of 939.83%. The company had revenue of $2.60 million during the quarter, compared to analysts’ expectations of $0.27 million. equities research analysts expect that Abeona Therapeutics will post -0.7 EPS for the current year.
Several hedge funds have recently modified their holdings of the stock. Millennium Management LLC boosted its stake in shares of Abeona Therapeutics by 2,357.3% in the first quarter. Millennium Management LLC now owns 916,256 shares of the biopharmaceutical company’s stock valued at $13,148,000 after buying an additional 878,969 shares during the period. Nexthera Capital LP bought a new stake in shares of Abeona Therapeutics in the first quarter valued at approximately $5,302,000. Sabby Management LLC bought a new stake in shares of Abeona Therapeutics in the first quarter valued at approximately $187,000. UBS Group AG raised its position in Abeona Therapeutics by 36.5% during the first quarter. UBS Group AG now owns 152,081 shares of the biopharmaceutical company’s stock valued at $2,182,000 after purchasing an additional 40,680 shares in the last quarter. Finally, Knott David M acquired a new position in Abeona Therapeutics during the first quarter valued at approximately $101,000. Institutional investors and hedge funds own 69.11% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.